Erik Magnusson

Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden.

Stockholm Innovation & Growth AB is a Venture Capital firm, a subsidiary of Electrum Foundation founded in 1994 by Pär Hedberg. Stockholm Innovation & Growth AB is headquartered in Stockholm.

Disruptive Pharma AB is a pharmaceutical company based in Uppsala, Sweden, with a passion for innovation in drug products. The Swedish company has perfected the groundbreaking mesoporous magnesium carbonate (mmc) drug delivery technology, which makes it easier to develop amorphous drug candidates. By combining the mmc formulation technology with drug compounds, they can enhance existing products or assist in formulating new therapies. Disruptive Pharma seeks commercial partnership or licensing to industry partners within the drug improvement business area. The company was founded in 2018 by Maria Strömme, and the CEO is Peter Åsberg.

Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021.

Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden.

Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway.

NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden.

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

Part of Chalmers University of Technology Foundation, Encubator AB is an alternative investment manager. The company is based in Gothenburg, Sweden. The Swedish company was founded in 2004. The CEO is Jonas Berggren.

Immuneed AB develops drugs. The firm offers as a contract research organization and provides specialized services for immunotoxicology and immunophenotyping. Its services include cytokine release assay, complement activation, cellular drug biodistribution, cell activation patterns, immune recall responses, viability analyses, blood status and mode-of-action studies. The company was founded by Sara Mangsbo, Erika Fletcher and Thomas Totterman in 2014 and is headquartered in Uppsala, Sweden.

Haracon AB provides corporate consulting services.

Disruptive Materials AB manufactures mesoporous magnesium carbonate. It focuses on commercializing the material Upsalite that can be used in applications such as desiccant for humidity control, pharmaceutics, adsorbent for waste handling, thermal and acoustic insulation, cosmetics, adsorbent in ink jet paper,and bio material applications. The company was founded by Johan A. V. Gómez de la Torre, Maria Strømme, Lars-Erik Mattias Karls, and Sara Kristina Frykstrand Ångström in December 2011 and is headquartered in Uppsala, Sweden.

Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden.

LU Holding AB (LU Holding) is a venture capital subsidiary of University of Lund founded in 1994. The firm is headquartered in Lund, Sweden.

Brookhaven Instruments AB provides monitoring systems for clean rooms, portable particle counters, filter testing equipment, sterilization equipment, air samplers, validation, and measurement services. Brookhaven Instruments is based in Hallstahammar, SE. The Swedish company aims to be a leading supplier in the field, offering everything from design and installation to validation, training, and maintenance work.

NNE AB provides consulting and engineering solutions for pharmaceutical and biotech companies. The firm also produces pharmaceutical products. The company was founded in 2002 and is headquartered in Stockholm, Sweden.

Saga Diagnostics AB operates as a personalized cancer medicine and disease monitoring company. The firm's services include Gene Mutation analysis, circulating tumor DNA and Chromosome analysis. The company was founded by Lao Saal and Anthony George in 2016 and is headquartered in Lund, Sweden.

Akuru Pharma AB engages in the development of research and technology. It focuses on exploiting the abnormal expression of transporter proteins in kidney cancer for developing novel diagnostic and treatment modalities. The company was founded by Jennifer Hansson, Hakan Axelson, and Johanna Asklin on April 14, 2016 and is headquareterd in Lund, Sweden.

SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden.